| Megan Mcnutt, | |
|
1000 Lincoln St, Emporia, KS 66801-2449 | |
| (620) 343-2211 | |
| (620) 342-1021 |
| Full Name | Megan Mcnutt |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 1000 Lincoln St, Emporia, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083481782 | NPI | - | NPPES |
| 03250 | Other | KS | BSRB |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Megan Mcnutt, 1000 Lincoln St, Emporia, KS 66801-2449 Ph: (620) 343-2211 | Megan Mcnutt, 1000 Lincoln St, Emporia, KS 66801-2449 Ph: (620) 343-2211 |
News Archive
Whitehead Institute scientists have created a method that site-specifically modifies proteins to exert control over their properties when administered therapeutically. The technique should be useful to increase potency, slow metabolism, and improve thermal stability of therapeutically useful proteins, such as interferon alpha 2 (IFN-alpha 2), which is used to treat variety of diseases, including leukemia, melanoma, and chronic hepatitis C.
ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
Immunotec Inc. announced today the enrollment of the first patient in the US Cancer trial of IMN 1207 being run at Beaumont Hospital's Community Clinical Oncology Program (CCOP) in Royal Oak, Michigan. The goal of the study is to determine the effect of IMN 1207, a cysteine-rich whey protein supplement, in preventing additional weight loss in patients with stage IV (advanced) non-small cell lung cancer.
ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study's main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.
› Verified 6 days ago
Samantha Thibodeau, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 Fax: 620-342-1021 | |
Tegan Jae Fanders, T-LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 | |
Dave L Provorse, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 | |
Jayme Collins, LCP, LMLP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 | |
Kristi Gildner, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 Fax: 620-342-1021 | |
Ms. Kathleen A Phillips, RN,LMLP,LCP Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Lincoln St, Emporia, KS 66801 Phone: 620-343-2211 Fax: 620-342-1021 |